Omalizumab for severe atopic dermatitis in 4- to 19-year-olds: the ADAPT RCT (2022)
Attributed to:
A randomised placebo-controlled study examining the role of anti-IgE in severe recalcitrant paediatric atopic eczema
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3310/wcxn5739
PubMed Identifier: 35679442
Publication URI: http://europepmc.org/abstract/MED/35679442
Type: Journal Article/Review
Parent Publication: Efficacy and Mechanism Evaluation
Issue: 5